166 related articles for article (PubMed ID: 35182276)
61. Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen.
Brennan DJ; Laursen H; O'Connor DP; Borgquist S; Uhlen M; Gallagher WM; Pontén F; Millikan RC; Rydén L; Jirström K
Breast Cancer Res; 2011 Jan; 13(1):R12. PubMed ID: 21281480
[TBL] [Abstract][Full Text] [Related]
62. ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling.
Gelsomino L; Gu G; Rechoum Y; Beyer AR; Pejerrey SM; Tsimelzon A; Wang T; Huffman K; Ludlow A; Andò S; Fuqua SAW
Breast Cancer Res Treat; 2016 Jun; 157(2):253-265. PubMed ID: 27178332
[TBL] [Abstract][Full Text] [Related]
63. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.
Ravdin PM; Green S; Dorr TM; McGuire WL; Fabian C; Pugh RP; Carter RD; Rivkin SE; Borst JR; Belt RJ
J Clin Oncol; 1992 Aug; 10(8):1284-91. PubMed ID: 1634918
[TBL] [Abstract][Full Text] [Related]
64. Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.
Luen SJ; Asher R; Lee CK; Savas P; Kammler R; Dell'Orto P; Biasi OM; Demanse D; JeBailey L; Dolan S; Hackl W; Thuerlimann B; Viale G; Colleoni M; Regan MM; Loi S
JAMA Oncol; 2018 Oct; 4(10):1335-1343. PubMed ID: 29902286
[TBL] [Abstract][Full Text] [Related]
65. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients.
Liu S; Chia SK; Mehl E; Leung S; Rajput A; Cheang MC; Nielsen TO
Breast Cancer Res Treat; 2010 Jan; 119(1):53-61. PubMed ID: 19205877
[TBL] [Abstract][Full Text] [Related]
66. Factors predictive of response to hormone therapy in breast cancer.
Rastelli F; Crispino S
Tumori; 2008; 94(3):370-83. PubMed ID: 18705406
[TBL] [Abstract][Full Text] [Related]
67. Genomic index of sensitivity to endocrine therapy for breast cancer.
Symmans WF; Hatzis C; Sotiriou C; Andre F; Peintinger F; Regitnig P; Daxenbichler G; Desmedt C; Domont J; Marth C; Delaloge S; Bauernhofer T; Valero V; Booser DJ; Hortobagyi GN; Pusztai L
J Clin Oncol; 2010 Sep; 28(27):4111-9. PubMed ID: 20697068
[TBL] [Abstract][Full Text] [Related]
68. Determination of estrogen receptors in paraffin-embedded tissue. Techniques and the value in breast cancer treatment.
Andersen J
Acta Oncol; 1992; 31(6):611-27. PubMed ID: 1281648
[TBL] [Abstract][Full Text] [Related]
69. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.
Swain SM; Wilson JW; Mamounas EP; Bryant J; Wickerham DL; Fisher B; Paik S; Wolmark N
J Natl Cancer Inst; 2004 Apr; 96(7):516-23. PubMed ID: 15069113
[TBL] [Abstract][Full Text] [Related]
70. Discovery of breast cancer risk genes and establishment of a prediction model based on estrogen metabolism regulation.
Zhao F; Hao Z; Zhong Y; Xu Y; Guo M; Zhang B; Yin X; Li Y; Zhou X
BMC Cancer; 2021 Feb; 21(1):194. PubMed ID: 33632172
[TBL] [Abstract][Full Text] [Related]
71. The role of genetic breast cancer susceptibility variants as prognostic factors.
Fasching PA; Pharoah PD; Cox A; Nevanlinna H; Bojesen SE; Karn T; Broeks A; van Leeuwen FE; van't Veer LJ; Udo R; Dunning AM; Greco D; Aittomäki K; Blomqvist C; Shah M; Nordestgaard BG; Flyger H; Hopper JL; Southey MC; Apicella C; Garcia-Closas M; Sherman M; Lissowska J; Seynaeve C; Huijts PE; Tollenaar RA; Ziogas A; Ekici AB; Rauh C; Mannermaa A; Kataja V; Kosma VM; Hartikainen JM; Andrulis IL; Ozcelik H; Mulligan AM; Glendon G; Hall P; Czene K; Liu J; Chang-Claude J; Wang-Gohrke S; Eilber U; Nickels S; Dörk T; Schiekel M; Bremer M; Park-Simon TW; Giles GG; Severi G; Baglietto L; Hooning MJ; Martens JW; Jager A; Kriege M; Lindblom A; Margolin S; Couch FJ; Stevens KN; Olson JE; Kosel M; Cross SS; Balasubramanian SP; Reed MW; Miron A; John EM; Winqvist R; Pylkäs K; Jukkola-Vuorinen A; Kauppila S; Burwinkel B; Marme F; Schneeweiss A; Sohn C; Chenevix-Trench G; ; Lambrechts D; Dieudonne AS; Hatse S; van Limbergen E; Benitez J; Milne RL; Zamora MP; Pérez JI; Bonanni B; Peissel B; Loris B; Peterlongo P; Rajaraman P; Schonfeld SJ; Anton-Culver H; Devilee P; Beckmann MW; Slamon DJ; Phillips KA; Figueroa JD; Humphreys MK; Easton DF; Schmidt MK
Hum Mol Genet; 2012 Sep; 21(17):3926-39. PubMed ID: 22532573
[TBL] [Abstract][Full Text] [Related]
72. Association of SNP-SNP Interactions Between RANKL, OPG, CHI3L1, and VDR Genes With Breast Cancer Risk in Egyptian Women.
Shaker OG; Senousy MA
Clin Breast Cancer; 2019 Feb; 19(1):e220-e238. PubMed ID: 30309792
[TBL] [Abstract][Full Text] [Related]
73. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.
Nielsen TO; Parker JS; Leung S; Voduc D; Ebbert M; Vickery T; Davies SR; Snider J; Stijleman IJ; Reed J; Cheang MC; Mardis ER; Perou CM; Bernard PS; Ellis MJ
Clin Cancer Res; 2010 Nov; 16(21):5222-32. PubMed ID: 20837693
[TBL] [Abstract][Full Text] [Related]
74. Machine learning identifies interacting genetic variants contributing to breast cancer risk: A case study in Finnish cases and controls.
Behravan H; Hartikainen JM; Tengström M; Pylkäs K; Winqvist R; Kosma VM; Mannermaa A
Sci Rep; 2018 Sep; 8(1):13149. PubMed ID: 30177847
[TBL] [Abstract][Full Text] [Related]
75. The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.
Tapper W; Hammond V; Gerty S; Ennis S; Simmonds P; Collins A; ; Eccles D
Breast Cancer Res; 2008; 10(6):R108. PubMed ID: 19094228
[TBL] [Abstract][Full Text] [Related]
76. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
[TBL] [Abstract][Full Text] [Related]
77. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG
J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153
[TBL] [Abstract][Full Text] [Related]
78. The correlation of estrogen and progesterone receptor levels with response to chemotherapy for advanced carcinoma of the breast.
Paone JF; Abeloff MD; Ettinger DS; Arnold EA; Baker RR
Surg Gynecol Obstet; 1981 Jan; 152(1):70-4. PubMed ID: 7455895
[TBL] [Abstract][Full Text] [Related]
79. Estrogen receptor alpha polymorphisms and the risk of malignancies.
Anghel A; Narita D; Seclaman E; Popovici E; Anghel M; Tamas L
Pathol Oncol Res; 2010 Dec; 16(4):485-96. PubMed ID: 20383761
[TBL] [Abstract][Full Text] [Related]
80. Significant association between ERCC2 and MTHR polymorphisms and breast cancer susceptibility in Moroccan population: genotype and haplotype analysis in a case-control study.
Hardi H; Melki R; Boughaleb Z; El Harroudi T; Aissaoui S; Boukhatem N
BMC Cancer; 2018 Mar; 18(1):292. PubMed ID: 29544444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
